Yttrium-90 - current status, expected availability and applications of a high beta energy emitter

R. Leyva Montaña, I. Hernández González, A. Alberti Ramirez, L. Garaboldi, M. Chinol

Research output: Contribution to journalArticle

Abstract

Yttrium-90 (90Y, T1/2 64.14 h) is a key example of a high beta energy-emitting radionuclide which is available from the strontium-90 (90Sr)/90Y radionuclide generator system. Clinical uses of 90Y-labeled radiopharmaceutical agents have been pursued for many years and many applications have proven to be clinical effective. These most notably include the application of 90Y-labeled antibodies for a variety of applications such as for effective treatment of non-Hodgkin's lymphoma. One of the major advantages for use of 90Y is ready availability from the very long-lived 90Sr parent (T1/2 28.78 y). Because of the importance of maintaining generator performance and minimizing parent breakthrough, this paper describes development, use and quality control of both high capacity cation adsorption-type and electrochemical generator systems. In addition, the preparation and targeting to tumors in mice of DOTA-conjugated Nimotuzamab (h-R3) antibody which recognizes the external domain of the EPFR antibody radiolabeled with 90Y obtained from the electrochemical generator is also described. As a key example for clinical applications of 90Y, the use of 90Y-labeled biotin for intra-operative pre-targeting for radionuclide therapy (IART®) of breast cancer is also described.

Original languageEnglish
Pages (from-to)253-263
Number of pages11
JournalCurrent Radiopharmaceuticals
Volume5
Issue number3
Publication statusPublished - Jul 2012

    Fingerprint

Keywords

  • Sr impurity
  • Sr/Y generators
  • Antibody radiolabeling
  • Biotin radiolabeling
  • Pre-targeting approach

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Leyva Montaña, R., Hernández González, I., Alberti Ramirez, A., Garaboldi, L., & Chinol, M. (2012). Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. Current Radiopharmaceuticals, 5(3), 253-263.